Intracoronary compared to intravenous abciximab in patients with st segment elevation myocardial infarction treated with primary percutaneous coronary intervention reduces mortality, target vessel revascularization and reinfarction after 1 year
Cardiology, 11/23/2011Iversen AZ et al.
In pPCI–treated ST segment elevation myocardial infarction (STEMI) patients treated with abciximab, intracoronary (IC) bolus administration resulted in a significant reduction in mortality, target vessel revascularization (TVR) and myocardial infarction (MI) compared to intravenous (IV) bolus administration.
A total of 355 pPCI–treated STEMI patients were randomized to either IC or IV bolus abciximab followed by a 12–hour IV infusion.
Patients were followed for 1 year to observe mortality, TVR or myocardial infarction (MI) and the combination of these.
The two treatment arms (IV, n = 170; IC, n = 185) were similar with regard to baseline characteristics.
Mortality was reduced from 10% in the IV group to 2.7% in the IC group (p = 0.004).
TVR and MI were also reduced with IC administration (TVR: 14.1 vs. 7.6%, p = 0.04; MI: 11.8 vs. 5.4%, p = 0.03).
Consequently, patients in the IC treatment arm had a relative risk reduction of 55% for the combined endpoint after 1 year (p = 0.002) compared to the IV treatment arm.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.